LeonaBio annual free cash flow
2020
2021
2022
2023
2024
LeonaBio reported −$97.2M in free cash flow for fiscal 2024, an increase of $3.9M from the previous fiscal year.
View full LeonaBio company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$97.2M | $3.9M | — | — |
| 2023 | 2023-12-31 | −$101.1M | −$27.4M | — | — |
| 2022 | 2022-12-31 | −$73.6M | −$28.9M | — | — |
| 2021 | 2021-12-31 | −$44.7M | −$18.2M | — | — |
| 2020 | 2020-12-31 | −$26.4M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$26.0M | $280,000 | — | — |
| Q3 2024 | 2024-09-30 | −$23.0M | $991,000 | — | — |
| Q2 2024 | 2024-06-30 | −$22.4M | $2.0M | — | — |
| Q1 2024 | 2024-03-31 | −$25.8M | $626,000 | — | — |
| Q4 2023 | 2023-12-31 | −$26.3M | −$10.6M | — | — |
| Q3 2023 | 2023-09-30 | −$24.0M | −$2.1M | — | — |
| Q2 2023 | 2023-06-30 | −$24.3M | −$5.6M | — | — |
| Q1 2023 | 2023-03-31 | −$26.4M | −$9.1M | — | — |
| Q4 2022 | 2022-12-31 | −$15.7M | $3.5M | — | — |
| Q3 2022 | 2022-09-30 | −$21.9M | −$11.5M | — | — |
| Q2 2022 | 2022-06-30 | −$18.7M | −$11.3M | — | — |
| Q1 2022 | 2022-03-31 | −$17.3M | −$9.7M | — | — |
| Q4 2021 | 2021-12-31 | −$19.2M | — | — | — |
| Q3 2021 | 2021-09-30 | −$10.4M | — | — | — |
| Q2 2021 | 2021-06-30 | −$7.4M | — | — | — |
| Q1 2021 | 2021-03-31 | −$7.6M | — | — | — |
LeonaBio's latest reported quarter, Q4 2024, generated −$26.0M in free cash flow, an increase of $280,000 year over year.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review LeonaBio filings at SEC.gov ↗